Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

Peter Manza, Annabelle M. Belcher, Heather Fitzsimons, Max Spaderna, Aaron D. Greenblatt, Hannah C. Smith, Meghan Derenoncourt, Donald Gann, Umer Farooq, Mark D. Kvarta, Bethany A. DiPaula, Sarah Merritt, Ivana Mitic, Carlos A. Zarate, Todd D. Gould, Eric Weintraub, Sarah M. Kattakuzhy

Open source

DOI: 10.1080/00952990.2025.2541212
Published: 2025-08-22
Container: The American Journal of Drug and Alcohol Abuse
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/00952990.2025.2541212,
  title = {Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression},
  author = {Peter Manza and Annabelle M. Belcher and Heather Fitzsimons and Max Spaderna and Aaron D. Greenblatt and Hannah C. Smith and Meghan Derenoncourt and Donald Gann and Umer Farooq and Mark D. Kvarta and Bethany A. DiPaula and Sarah Merritt and Ivana Mitic and Carlos A. Zarate and Todd D. Gould and Eric Weintraub and Sarah M. Kattakuzhy},
  year = {2025},
  journal = {The American Journal of Drug and Alcohol Abuse},
  doi = {10.1080/00952990.2025.2541212},
  url = {https://doi.org/10.1080/00952990.2025.2541212}
}

RIS

TY  - JOUR
TI  - Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression
AU  - Peter Manza
AU  - Annabelle M. Belcher
AU  - Heather Fitzsimons
AU  - Max Spaderna
AU  - Aaron D. Greenblatt
AU  - Hannah C. Smith
AU  - Meghan Derenoncourt
AU  - Donald Gann
AU  - Umer Farooq
AU  - Mark D. Kvarta
AU  - Bethany A. DiPaula
AU  - Sarah Merritt
AU  - Ivana Mitic
AU  - Carlos A. Zarate
AU  - Todd D. Gould
AU  - Eric Weintraub
AU  - Sarah M. Kattakuzhy
PY  - 2025
JO  - The American Journal of Drug and Alcohol Abuse
DO  - 10.1080/00952990.2025.2541212
UR  - https://doi.org/10.1080/00952990.2025.2541212
ER  -

APA

Manza, P., Belcher, A. M., Fitzsimons, H., Spaderna, M., Greenblatt, A. D., Smith, H. C., Derenoncourt, M., Gann, D., Farooq, U., Kvarta, M. D., DiPaula, B. A., Merritt, S., Mitic, I., Zarate, C. A., Gould, T. D., Weintraub, E., & Kattakuzhy, S. M. (2025). Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2025.2541212

Source records

crossref · retrieved 2026-09-26T03:52:07.440Z